Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcoma.

Frontiers in immunology - 1 Jan 2026

Mannah Brie-Anne, Yang Fei, Yu Lijia, Gurney Howard, Yang Jean Y H, Park John J, Lim Su Yin

Abstract excerpt

Introduction: Chemotherapy remains the standard of care for metastatic soft tissue sarcoma (STS), but clinical benefit is modest. Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD-1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), have transformed cancer treatment, yet their efficacy in STS is variable and largely confined to undifferentiated pleomorphic sarcoma (UPS) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Leukocytes, Mononuclear

Share to Programmed Cell Death 1 Receptor

Share to Sarcoma

Source

Open in PubMed Open full text

Identifiers

PMID: 41869350
DOI: 10.3389/fimmu.2026.1783216
PMCID: PMC12999908

Genes

STS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcoma.PMID 41869350Read ↗

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcomaSemantic proximity Read ↗

Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint BlockadeSemantic proximity Read ↗

CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomesSemantic proximity Read ↗

B cells are associated with survival and immunotherapy response in sarcoma.Semantic proximity Read ↗

The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic StudySemantic proximity Read ↗

Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypesSemantic proximity Read ↗

Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies.Semantic proximity Read ↗

New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular SubtypeSemantic proximity Read ↗

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibitionSemantic proximity Read ↗

The proteomic landscape of soft tissue sarcomasSemantic proximity Read ↗

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanibSemantic proximity Read ↗

Molecular biomarkers impact survival after neoadjuvant chemoradiation in locally advanced soft tissue sarcoma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.